US FDA to convene expert panel to review wider access to some peptides Reuters FDA's Overreach on Compounded Peptides The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Big news in the peptide world. , The FDA has scheduled a formal hearing in July to review 7 peptides including BPC 157 and TB 500 for legal compounding. , This isnt approval. But its On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver